Background
Materials and methods
Human subjects and tissue specimens
Sample processing and genomic DNA bisulfite treatment
PTPRO gene promoter methylation analysis
Statistical analyses
Results
Prevalence of PTPRO methylation in sporadic primary breast cancer tissues
Correlation of PTPRO methylation with clinicopathologic parameters
Total no. | PTPRO methylated | PTPRO unmethylated | χ2 | P-value | |||
---|---|---|---|---|---|---|---|
NO | % | NO | % | ||||
All | 175 | 130 | 74.3 | 45 | 25.7 | ||
Age at diagnosis, years | |||||||
<45 | 56 | 46 | 82.1 | 10 | 17.9 | 2.662 | 0.103 |
> = 45 | 119 | 84 | 70.6 | 35 | 29.4 | ||
pT | |||||||
0-1 | 12 | 7 | 58.3 | 5 | 41.7 | 3.885 | 0.146 |
2 | 118 | 93 | 78.8 | 25 | 21.2 | ||
3-4 | 40 | 27 | 67.5 | 13 | 32.5 | ||
NA | 5 | 3 | 2 | ||||
pN | |||||||
0 | 74 | 51 | 68.9 | 23 | 31.1 | 7.75 | 0.051 |
1 | 41 | 27 | 65.9 | 14 | 34.1 | ||
2 | 43 | 37 | 86.0 | 6 | 14.0 | ||
3 | 16 | 14 | 87.5 | 2 | 12.5 | ||
NA | 3 | 2 | 1 | ||||
Clinical stage | |||||||
I + II | 95 | 68 | 71.6 | 27 | 28.4 | 1.325 | 0.25 |
III | 77 | 61 | 79.2 | 16 | 20.8 | ||
NA | 3 | 1 | 2 | ||||
Tumor grade | |||||||
G1 + G2 | 105 | 72 | 68.6 | 33 | 31.4 | 4.481 |
0.028
|
G3 | 67 | 56 | 83.6 | 11 | 16.4 | ||
NA | 3 | 2 | 1 | ||||
Estrogen receptor | |||||||
negative | 53 | 43 | 81.1 | 10 | 18.9 | 2.432 | 0.119 |
positive | 105 | 73 | 69.5 | 32 | 30.5 | ||
NA | 17 | 14 | 3 | ||||
Progesterone receptor | |||||||
negative | 84 | 66 | 78.6 | 18 | 21.4 | 2.448 | 0.118 |
positive | 74 | 50 | 67.6 | 24 | 32.4 | ||
NA | 17 | 14 | 3 | ||||
HER2 | |||||||
negative | 80 | 59 | 73.8 | 21 | 26.3 | 0.009 | 0.924 |
positive | 78 | 57 | 73.1 | 21 | 26.9 | ||
NA | 17 | 14 | 3 | ||||
Menopausal status | |||||||
premenopausal | 94 | 75 | 79.8 | 19 | 20.2 | 2.376 | 0.123 |
postmenopausal | 79 | 55 | 69.6 | 24 | 30.4 | ||
NA | 2 | 0 | 2 |
Prognostic value of breast cancer subtypes determined by PTPRO methylation status
Clinicopathological parameters | Univariate analysis | Multivariate analysis | ||||
---|---|---|---|---|---|---|
Hazard ratio | CI 95% | P-value | Hazard ratio | CI 95% | P- value | |
Estrogen receptor | ||||||
positive (vs. negative) | 0.737 | 0.285-1.906 | 0.530 | |||
Progesterone receptor | ||||||
positive (vs. negative) | 0.559 | 0.214-1.458 | 0.235 | |||
HER2 | ||||||
positive (vs. negative) | 1.765 | 0.661-4.716 | 0.257 | |||
Hormone receptor | ||||||
positive (vs. negative) | 0.737 | 0.285-1.906 | 0.530 | |||
Age | ||||||
> = 45 (vs. <45) | 1.886 | 0.626-5.684 | 0.260 | |||
Histological grade | ||||||
III (vs. II & I ) | 2.572 | 1.238-5.342 |
0.011
| |||
pT | ||||||
4 & 3 (vs. 2 & 1) | 1.724 | 0.996-2.985 | 0.052 | 1.77 | 1.005-3.118 |
0.048
|
pN | ||||||
positive (vs. negative) | 4.343 | 1.263-14.933 |
0.020
| 4.40 | 1.238-15.673 |
0.022
|
Stage | ||||||
III (vs. II & I ) | 1.985 | 0.878-4.489 | 0.100 | |||
PTPRO methylation | ||||||
methylated (vs. unmethylated) | 3.273 | 0.754-14.209 | 0.113 | |||
PTPRO methylation & HER2 status | ||||||
Methylated/HER2+ (vs. others) | 2.749 | 1.065-7.097 |
0.037
| 3.663 | 1.371-9.784 |
0.010
|
PTPRO methylation as a peripheral blood biomarker for breast cancer
Patient NO. | Tumor | Plasma | HER2 | ER | PR | Age | Grade | pT | pN | pM |
---|---|---|---|---|---|---|---|---|---|---|
1 | ● | ● | + | - | - | 52 | 2 | 2 | 1 | 0 |
2 | ● | ● | + | - | - | 49 | 2 | 2 | 0 | 0 |
3 | ● | ● | + | - | - | 41 | 2 | 3 | 1 | 0 |
4 | ● | ● | - | - | - | 41 | 3 | 2 | 0 | 0 |
5 | ● | ● | - | + | + | 89 | 3 | 4 | x | 0 |
6 | ● | ● | - | + | - | 58 | 3 | 4 | 2 | 0 |
7 | ● | ● | - | + | - | 57 | 2 | 4 | 2 | 0 |
8 | ● | ● | - | + | - | 57 | 1 | 2 | 0 | 0 |
9 | ● | ● | - | + | - | 54 | 2 | 2 | 0 | 0 |
10 | ● | ● | - | + | + | 30 | 3 | 3 | 3 | 0 |
11 | ● | ● | - | - | - | 48 | 1 | 4 | 2 | 0 |
12 | ● | ○ | + | + | + | 42 | 3 | 4 | 2 | 0 |
13 | ● | ○ | + | - | - | 52 | 2 | 2 | 0 | 0 |
14 | ● | ○ | + | + | + | 45 | 2 | 4 | 2 | 0 |
15 | ● | ○ | - | + | + | 57 | 2 | 2 | 1 | 0 |
16 | ● | ○ | - | + | - | 62 | 2 | 2 | 2 | 0 |
17 | ● | ○ | - | + | + | 46 | 2 | 4 | 3 | 0 |
18 | ● | ○ | - | + | + | 60 | 3 | 2 | 2 | 0 |
19 | ○ | ○ | + | + | - | 42 | 1 | 2 | 1 | 0 |
20 | ○ | ○ | + | - | - | 61 | 3 | 3 | 0 | 0 |
21 | ○ | ○ | - | + | - | 36 | 2 | 3 | 3 | 0 |
22 | ○ | ○ | - | + | + | 50 | 1 | 1 | 0 | 0 |
23 | ○ | ○ | - | + | - | 54 | 3 | 3 | 0 | 0 |
24 | ○ | ○ | - | + | - | 54 | 2 | 1 | 0 | 0 |
Methylation ratio (%) | 18/24 (75.0) | 11/24 (45.8) |